Veklury Recalled Due to Risk of Glass Particle Contamination
Gilead has recalled one lot of Veklury (remdesivir) after confirming the presence of a glass particle in a vial following a customer complaint.
Tag: Gilead Sciences
All
Latest
Veklury Recalled Due to Risk of Glass Particle Contamination
Gilead has recalled one lot of Veklury (remdesivir) after confirming the presence of a glass particle in a vial following a customer complaint.
Read More
Remdesivir Reduced COVID-19 Mortality, Hospital Readmission Rates Across All VariantsÂ
One analysis found that early administration of remdesivir in vulnerable patient populations resulted in an overall 25% lower risk of mortality at day 28 across all variant time periods.
Read MoreFDA Expands Approval of Remdesivir for Pediatric Patients
The US FDA expanded the approval of remdesivir (Veklury, Gilead Sciences) to include pediatric patients 28 days of age and older weighing at least 3 kg with positive results of direct SARS-CoV-2 viral testing.
Read MoreRemdesivir Reduced Hospitalization Risk, Mortality
Participants receiving a three-day course of remdesivir (Veklury, Gilead Sciences) had an 87% reduction in risk of COVID-19-related hospitalization or all-cause death by Day 28 and an 81% reduction in the risk of COVID-19-related medical visits or all-cause death by Day 28 compared to placebo.
Read More
Gilead Puts Multiple Price Tags on COVID-19 Therapeutic Remdesivir
Gilead announced Remdesivir drug prices vary based on US insurance coverage. Generics are also being manufactured for developing nations.
Read More
India OK’s Generic Remdesivir for COVID-19
India has approved the manufacturing and marketing of a generic version of Gilead Sciences’ COVID-19 treatment remdesivir, Reuters reports.
Read More
Gilead Contributes $100K to ATS COVID-19 Crisis Fund
The American Thoracic Society has received a $100,000 donation from Gilead Sciences Inc to support the ATS COVID-19 Crisis Fund.
Read More
Remdesivir Has “Clear-cut” Benefits for COVID-19
The investigational antiviral remdesivir “has a clear-cut, positive effect in diminishing the time to recovery” for patients infected with COVID-19, NIAID director Anthony Fauci says.
Read More
New RSV Drug Shows Positive Results
A phase 2a challenge study for GS-5806, an investigational oral RSV fusion inhibitor, found that the drug safely reduced the viral load and clinical illness of healthy adult volunteers who were intranasally infected with respiratory syncytial virus.
Read More